Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2017 | Pages:
63 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Rosacea - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H2 2017, provides an overview of the Rosacea (Dermatology) pipeline landscape. Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 7, 7 and 1 respectively. Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology). - The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Rosacea (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Rosacea (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Rosacea - Overview 7 Rosacea - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Products under Development by Companies 11 Rosacea - Therapeutics Assessment 12 Assessment by Target 12 Assessment by Mechanism of Action 14 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Rosacea - Companies Involved in Therapeutics Development 20 Almirall SA 20 Amorepacific Corp 20 BioPharmX Inc 21 Cutanea Life Sciences Inc 21 ELORAC Inc 21 Foamix Pharmaceuticals Ltd 22 Hovione FarmaCiencia SA 22 Promius Pharma LLC 23 Sol-Gel Technologies Ltd 23 Rosacea - Drug Profiles 24 AC-701 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 ACUD-1 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 ADP-13612 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 benzoyl peroxide - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 carbamide peroxide - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 DFD-29 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 DMT-210 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 DMT-220 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 EP-0003 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 FMX-103 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 itraconazole - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 minocycline - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 minocycline - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 MSB-03 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 omiganan pentahydrochloride - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 PAC-14028 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 phenylbutyrate - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Rosacea - Dormant Projects 50 Rosacea - Discontinued Products 52 Rosacea - Product Development Milestones 53 Featured News & Press Releases 53 Jun 12, 2017: Foamix Announces Dosing of First Patient in Phase 3 Rosacea Clinical Trials for FMX103 Minocycline Foam 1.5% 53 Jan 18, 2017: Dermata Therapeutics Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study 53 Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients 54 Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea 54 Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea 55 May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea 55 May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study 56 May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea 56 Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea 57 Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 57 Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 58 Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 58 Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 59 Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 60 Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 60 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 62 Disclaimer 63
List of Tables
Number of Products under Development for Rosacea, H2 2017 8 Number of Products under Development by Companies, H2 2017 10 Products under Development by Companies, H2 2017 11 Number of Products by Stage and Target, H2 2017 13 Number of Products by Stage and Mechanism of Action, H2 2017 15 Number of Products by Stage and Route of Administration, H2 2017 17 Number of Products by Stage and Molecule Type, H2 2017 19 Rosacea - Pipeline by Almirall SA, H2 2017 20 Rosacea - Pipeline by Amorepacific Corp, H2 2017 20 Rosacea - Pipeline by BioPharmX Inc, H2 2017 21 Rosacea - Pipeline by Cutanea Life Sciences Inc, H2 2017 21 Rosacea - Pipeline by ELORAC Inc, H2 2017 21 Rosacea - Pipeline by Foamix Pharmaceuticals Ltd, H2 2017 22 Rosacea - Pipeline by Hovione FarmaCiencia SA, H2 2017 22 Rosacea - Pipeline by Promius Pharma LLC, H2 2017 23 Rosacea - Pipeline by Sol-Gel Technologies Ltd, H2 2017 23 Rosacea - Dormant Projects, H2 2017 50 Rosacea - Dormant Projects, H2 2017 (Contd..1), H2 2017 51 Rosacea - Discontinued Products, H2 2017 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
